AI Article Synopsis
- Reversal of severe tricuspid regurgitation is uncommon, but a case demonstrates that proper immunosuppression with standard heart failure treatments can lead to improvement.* -
- The patient had cardiac sarcoidosis, emphasizing the importance of specific therapy in managing this condition.* -
- The text highlights the diagnostic difficulties in differentiating cardiac sarcoidosis from other heart diseases in patients experiencing biventricular failure.*
Article Abstract
Reversal of torrential tricuspid regurgitation is rarely seen. We describe a case in which effective immunosuppression alongside conventional heart failure therapies lead to reversibility of torrential tricuspid regurgitation in a patient with cardiac sarcoidosis. We also discuss the diagnostic challenge in distinguishing cardiac sarcoidosis from other myocardial diseases in a patient presenting with biventricular failure.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558384 | PMC |
| http://dx.doi.org/10.1007/s12350-023-03307-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of catheter ablation in cardiac sarcoidosis patients with ventricular tachycardia: a propensity score-matched retrospective analysis.
J Interv Card Electrophysiol
January 2025
Cardiovascular Department, University of Texas Medical Branch, Galveston, TX, USA.
Background: Ventricular tachycardia (VT) in patients with cardiac sarcoidosis (CS) can lead to sudden cardiac death. The role of ventricular tachycardia ablation (VTA) in CS has been investigated in a few small, single-center, and larger observational studies, but the evidence still needs to be provided. This study aimed to investigate the clinical outcomes of VTA in patients with CS admitted with a diagnosis of VT.
View Article and Find Full Text PDFScreening for cardiac sarcoidosis: diagnostic approach and long-term follow-up in a tertiary centre.
Neth Heart J
January 2025
Department of Cardiology, Thorax Centre, Cardiovascular Institute, Erasmus Medical Centre, Rotterdam, The Netherlands.
Background: Cardiac sarcoidosis (CS) is associated with poor prognosis, making early diagnosis and treatment important. This study evaluated the results of a diagnostic approach in patients with known sarcoidosis and suspected cardiac involvement in a tertiary centre and their long-term outcomes.
Methods: We included 180 patients with sarcoidosis and a clinical suspicion of CS.
TNF alpha Inhibitors in Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis.
Crit Pathw Cardiol
December 2024
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Background: Recent studies have focused on treating cardiac sarcoidosis (CS) with corticosteroids primarily mitigating symptoms and reducing the risk of mortality and other cardiovascular complications. A promising new treatment approach involves tumor necrosis factor (TNF) alpha inhibitors.
Methodology: A systematic search was conducted on PubMed, the Cochrane Library, and Elsevier's Science Direct databases to identify studies comparing TNF alpha inhibitors with other drugs in CS patients who had heart failure.
Unusual presentation of necrotising sarcoid granulomatosis in the liver, spleen and bone.
BMJ Case Rep
January 2025
Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
Sarcoidosis is an inflammatory multisystem disease characterised by non-necrotising granulomas that typically affect the lungs, lymph nodes, eyes, skin, liver, spleen, heart, bones and joints. Although rare, necrotising granulomas can also occur. In this report, we present a case of a healthy woman in her 60s who presented with a 1-year history of fatigue and generalised body aches.
View Article and Find Full Text PDFPut Down the ACE: Low Clinical Utility for Angiotensin-Converting Enzyme Levels in Sarcoidosis: A Single-Center Retrospective Cohort Study.
J Clin Med
December 2024
Rheumatology Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
: ACE (angiotensin-converting enzyme) is considered a serological marker of sarcoidosis as elevated levels have been reported in 30-80% of patients. However, elevated ACE levels are also encountered in other medical conditions, and the clinical correlation between ACE levels and disease activity in sarcoidosis is disputable as well. To determine the significance of elevated ACE levels in the diagnosis and follow-up of sarcoidosis patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!